Sumary of Canakinumab fails to improve survival odds without ventilation in severe COVID-19:
- July 20, 2021 2 min read Source/Disclosures Published by: Disclosures: The researchers report funding Novartis.
- Caricchio additionally reports grants from Janssen and personal fees from Janssen, GlaxoSmithKline, Bristol Myers Squibb, Eli Lilly &
- Please see the study for all other authors’ relevant financial disclosures.
- Back to Healio Canakinumab fails to significantly increase the likelihood of survival without accompanying invasive mechanical ventilation, compared with placebo, in patients with severe COVID-19, according to data published in JAMA.
- “IL-1 is an upstream proinflammatory cytokine that is involved in the pathogenesis of a variety of autoinflammatory conditions and induces the production of secondary inflammatory mediators, including IL-6,” Roberto Caricchio, MD, of the Lewis Katz School of Medicine at Temple University, in Philadelphia, and colleagues wrote.
- 2021.9508. “Postmortem examination of lungs of patients who died of COVID-19 pneumonia have revealed intense inflammasome formation,” they added.
- ” To examine the efficacy of the IL-1 inhibitor canakinumab (Ilaris, Novartis), in patients who are hospitalized with severe COVID-19, Caricchio and colleagues conducted the CAN-COVID trial.
- According to the researchers, this randomized, double-blind, placebo-controlled phase 3 study included 454 participants with COVID-19 pneumonia from 39 hospitals in Europe and the United States.